Gilead Sciences
Executive Summary
Edward Jeglum, 41, joins nucleotide drug R&D firm as the exec VP-sales and marketing. Jeglum comes from Merck, where he most recently served as general manager of the West Point Pharma generic drug unit. David Doll, former director of marketing and managed care at Lemmon, succeeds Jeglum as the head of West Point Pharma.